Malignant Solid Neoplasms
Also known as: Malignant Solid Tumor / Malignant Solid Tumors / Malignant Solid Tumour / Solid Malignant Tumors / Malignant Solid Tumours / Solid Malignant Tumor / Malignant Solid Neoplasm / Disorder: Primary malignant neoplasm (disorder) / Malignant tumor (disorder) / Malignant neoplasms (& carcinoma) / Neoplasm malignant / Malignant neoplasm NOS (& sarcoma NOS) / Malignant neoplasm NOS / (Neoplasms) or (cancers) / Cancer / Malignant neoplasm of unspecified site NOS (disorder) / Ca - unspecified site NOS (disorder) / Ca - unspecified site NOS / (Ca unspecified site) or (secondary - unknown site) / Malignant tumor / Malignant tumour / [X]Malignant neoplasm without specification of site (disorder) / Malignant neoplasm of unspecified site (disorder) / Cancer (NOS) / Malignant neoplasm without specification of site
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB14723 | Larotrectinib | A kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments. |